Abstract

During chronic HIV infection, immune cells become increasingly dysfunctional and exhausted. Little is known about how immune functions are restored after initiation of antiretroviral therapy (ART). In this study, we assessed cellular and metabolic activity and evaluated the effect of individual antiretrovirals on cellular subsets ex vivo in ART-treated and treatment-naive chronically HIV-infected individuals. We observed that cellular respiration was significantly decreased in most immune cells in chronic HIV infection. The respiration was correlated to immune activation and the inhibitory receptor programmed cell death 1 on CD8+ T cells. ART restored the metabolic phenotype, but the respiratory impairment persisted in CD4+ T cells. This was particularly the case for individuals receiving integrase strand transfer inhibitors. CD4+ T cells from these individuals showed a significant reduction in ex vivo proliferative capacity compared with individuals treated with protease inhibitors or nonnucleoside reverse transcriptase inhibitors. We noticed a significant decrease in respiration of cells treated with dolutegravir (DLG) or elvitegravir (EVG) and a switch from polyfunctional to TNF-α–dominated “stress” immune response. There was no effect on glycolysis, consistent with impaired mitochondrial function. We detected increased levels of mitochondrial ROS and mitochondrial mass. These findings indicate that EVG and DLG use is associated with slow proliferation and impaired respiration with underlying mitochondrial dysfunction, resulting in overall decreased cellular function in CD4+ T cells.

Guidelines:
The Editorial Board will only consider letters that we deem relevant and of interest to our readers. We
will not post data that have not been subjected to peer review, nor will we post letters that are
essentially a reiteration of another letter. We reserve the right to edit any letter for length, content, and clarity.
Authors will be notified by e-mail if their letters were accepted. No appeals will be considered.

Specific requirements: All letters must be 400 words or fewer. You may enter the letter as plain
text or HTML. The author's name and e-mail address are required, and will be posted with the letter. All
possible conflicts of interest must be noted, even if they are not posted. If you wish to include a
figure (keep in mind that non-peer-reviewed data will not be posted), please contact the editors
directly at editors@the-jci.org.

First nameThis field is required

Last nameThis field is required

PositionThis field is required

InstitutionThis field is required

Email addressThis field is required

Other authors (Enter the list of colleagues in the following form: Stephanie Fulton, Thomas L. Wilding, and Frances Groen.)